Enclomiphene — your own testosterone, turned back up.

Enclomiphene is a selective estrogen receptor modulator (SERM) — the purified trans-isomer of clomiphene, the fertility medication used clinically for decades. Where clomiphene is a mix of two isomers (one of which, zuclomiphene, is estrogenic and lingers in the body), enclomiphene isolates the isomer that does the useful work for men.

It's taken as a once-daily capsule, compounded by a U.S.-licensed 503A pharmacy. Unlike testosterone itself, enclomiphene is not a controlled substance — no Ryan Haight in-person requirement, no Schedule III state restrictions, no DEA paperwork between you and your refill.

Your brain regulates testosterone through a feedback loop: the hypothalamus and pituitary watch circulating estrogen (made from testosterone) and dial production up or down. Enclomiphene blocks the estrogen receptors doing that watching — so the pituitary reads “low” and responds by releasing more LH and FSH, the hormones that tell the testes to make testosterone and sperm.

The result is more of your own testosterone, produced on your body's natural rhythm. Because LH and FSH go up rather than being suppressed (the opposite of what happens on TRT), testicular volume and sperm production are typically maintained — which is why enclomiphene is the first choice for men who may want children.

Three profiles fit enclomiphene especially well: men with borderline-low testosterone and real symptoms whose testes still respond to stimulation (typically younger men with secondary hypogonadism); men who plan to have children within the next few years and don't want TRT's fertility suppression; and men in states whose telehealth laws restrict Schedule III testosterone — enclomiphene, being non-controlled, remains available where injectable TRT isn't.

It's not the right tool for primary hypogonadism (testes that can't respond no matter how loud the signal) — that's a TRT conversation. Your physician sorts this out from your baseline labs: LH and FSH levels tell the story of where the problem lives.

Typical clinical use is 12.5–25 mg once daily, adjusted against follow-up labs. We start conservatively and titrate: a morning baseline panel before any prescription, a follow-up panel at 6–8 weeks to measure the response (total and free testosterone, LH, FSH, estradiol), and dose adjustment from the data.

Because it's a daily oral capsule, there's nothing to inject, nothing to refrigerate, and nothing that requires a quarterly supply box — refills ship like any other prescription.

Weeks 2–4: LH, FSH, and testosterone begin rising. Some men notice energy and libido shifts in this window; for others the subjective change lags the labs.

Weeks 6–8: the follow-up panel shows where your numbers landed. Typical responses raise total testosterone substantially above baseline — your physician reviews the result with you on a real call and adjusts.

Ongoing: quarterly check-ins and labs. Enclomiphene's effect is maintained while you take it; stopping returns you to your baseline over a few weeks, without the shutdown-recovery period TRT requires.

From $119/mo at list — founding-100 patients pay 10% below list, for life. Labs are billed pass-through at our pharmacy partner's cost ($88.25 for the standard male hormone panel, blood draw included). No membership fee.

Telehealth-native. Because enclomiphene is non-controlled, your care isn't hostage to the federal telemedicine rules that govern injectable testosterone. Where state law permits, follow-ups can be async — and the protocol is unaffected by the Schedule III telehealth restrictions that limit TRT in several states.

Honest fit-check first. Enclomiphene is a compounded preparation (not FDA-approved as a standalone product), and it isn't the right answer for every man — primary hypogonadism, certain pituitary conditions, and some lab patterns point to different tools. Your physician reviews your baseline panel line-by-line before prescribing anything, and will tell you plainly if TRT (or nothing at all) is the better path.